The invention generally relates to devices, systems, and methods for percutaneously suturing tissue. More particularly, the invention relates to a suturing device that includes at least two tissue engaging members connected to one another by an interconnecting member.
A septum is generally defined as a dividing muscular wall, membrane, or tissue between two or more bodily spaces. For example, the human heart is divided into four compartments or chambers. The left and right atria are located in the upper portion of the heart and the left and right ventricles are located in the lower portion of the heart. The left and right atria are separated from each other by the intraatrial septum, while the ventricles are separated by the intraventricular septum.
Septal defects can take various forms. An exemplary septal defect is a patent foramen ovale. The patent foramen ovale is a persistent, one-way, usually flap-like opening or tunnel in the wall between the right atrium and the left atrium of the heart. More specifically, the patent foramen ovale is formed by two layers of partially overlapping, but unfused, cardiac tissue (i.e., the septum primum and the septum secundum).
Under certain conditions, right atrial pressure exceeds left atrial pressure, creating the possibility for right to left shunting of blood through the patent foramen ovale. Blood clots may thereby enter the systemic circulation. This is particularly problematic for patients who are prone to forming venous thrombus, such as those with deep vein thrombosis or clotting abnormalities.
Improved devices, systems, and methods for suturing septal defects, such as, for example, patent foramen ovale, are needed.
The present invention relates to devices, systems, and methods for suturing together biological material, such as layers of tissue. In particular, in one embodiment, the present invention facilitates the percutaneous closure of a patent foramen ovale. According to an embodiment of the invention, the physician forms holes, for example, through the septum secundum and the septum primum in an area where the septa overlap. Subsequent to forming the holes, the physician positions the suturing device of the invention through the holes to bring into contact the two overlapping layers of tissue. Optionally, the physician also uses a tissue stabilization device to facilitate the procedure of closing the patent foramen ovale.
In general, in one aspect, the invention relates to a suturing system. The suturing system includes a suturing device, which itself includes first and second tissue engaging members and a first interconnecting member. The first tissue engaging member includes a first end, a second end, and a first intermediate portion positioned between the first end and the second end, while the second tissue engaging member includes a third end, a fourth end, and a second intermediate portion positioned between the third end and the fourth end. The first interconnecting member includes a first fixed end connected to the first intermediate portion of the first tissue engaging member, and a second fixed end connected to the second tissue engaging member. The suturing device is insertable into a patient in this connected configuration.
Various embodiments of this aspect of the invention include the following features. The second fixed end of the first interconnecting member may be connected to the second intermediate portion of the second tissue engaging member. The first and/or second tissue engaging members may be substantially cylindrical and they may have an atraumatic structure. For example, one or more ends of the first and/or second tissue engaging members may be rounded. In another embodiment, the first interconnecting member is made, either entirely or in part, from a resilient material. In one such embodiment, the first interconnecting member is reciprocally moveable between an unstressed position and a deformed position. In yet another embodiment, the first interconnecting member includes a stretchable material.
In still another embodiment, the tissue engaging members and/or the first interconnecting member include a material for stimulating tissue growth, such as, for example, collagen. Alternatively, the tissue engaging members and/or the first interconnecting member include a bioabsorbable material, such as, for example, a polylactic acid.
In one embodiment, the suturing device further includes a second interconnecting member connected to the first tissue engaging member and/or the second tissue engaging member. Moreover, the suturing device may further include a third tissue engaging member connected to the second interconnecting member, or, alternatively, to the first fixed end or the second fixed end of the first interconnecting member.
In a further embodiment, the suturing system also includes an elongate member. The elongate member includes a proximal end, a distal end, a wall extending from the proximal end to the distal end, and a cutting member positioned at the distal end. In one such embodiment, the wall of the elongate member defines a lumen that extends from the proximal end to the distal end of the elongate member, and the wall also defines an opening at the distal end of the elongate member. Moreover, the suturing device and a delivery member, which may be releasably connected to the suturing device, may be disposed within the lumen of the elongate member. Also, the elongate member may further include a retractable gate member positioned at the distal end of the elongate member. Alternatively, in another such embodiment, the first tissue engaging member includes a first lumen that extends from the first end to the second end of the first tissue engaging member, the second tissue engaging member includes a second lumen that extends from the third end to the fourth end of the second tissue engaging member, and the elongate member is disposed within the first lumen of the first tissue engaging member and also within the second lumen of the second tissue engaging member.
In another aspect, the invention provides another suturing device. The suturing device includes a first tissue engaging member, a second tissue engaging member, a first interconnecting member connecting the first tissue engaging member to the second tissue engaging member, and a first anchor connected to the first tissue engaging member.
In one embodiment of this aspect of the invention, the suturing device further includes a second anchor connected to the second tissue engaging member. One or both of the first anchor and the second anchor may be a spiral tissue anchor or a barbed tissue anchor.
In yet another aspect, the invention provides methods for suturing tissue. The methods include inserting one of the suturing devices described above into a heart of a patient and attaching the suturing device to one or more tissue surfaces in the heart of the patient.
In one embodiment of this aspect of the invention, the septum primum and the septum secundum are the tissue surfaces in the heart of the patient to which the suturing device is attached. In one such embodiment, the method for suturing tissue further includes positioning a tissue stabilization device in a patent foramen ovale.
In another embodiment, attaching the suturing device to the tissue surfaces in the heart of a patient includes extending the first tissue engaging member through a first hole in a first tissue layer and through a second hole in a second tissue layer, positioning the first tissue engaging member on a tissue surface of the second tissue layer, and positioning the second tissue engaging member on a tissue surface of the first tissue layer. Alternatively, in yet another embodiment, attaching the suturing device to the tissue surfaces in the heart of the patient includes extending the first tissue engaging member through a first hole in a first tissue layer, positioning the first tissue engaging member on a tissue surface of the first tissue layer, extending the second tissue engaging member through a second hole in a second tissue layer, and positioning the second tissue engaging member on a tissue surface of the second tissue layer.
The foregoing and other objects, aspects, features, and advantages of the invention will become more apparent from the following description and from the claims.
In the drawings, like reference characters generally refer to the same parts throughout the different views. Also, the drawings are not necessarily to scale, emphasis instead generally being placed on illustrating the principles and concepts of the invention.
The present invention relates to devices, systems, and methods for percutaneously suturing together biological material, such as layers of tissue. For example, in accordance with the invention, the septum primum and the septum secundum of a patent foramen ovale are sutured together.
Throughout the description, where devices are described as having, including, or comprising specific components, or where methods are described as having, including, or comprising specific method steps, it is contemplated that the devices of the present invention also consist essentially of, or consist of, the recited components, and that the methods of the present invention also consist essentially of, or consist of, the recited method steps.
In broad overview, a suturing device of the invention includes, in one embodiment, two tissue engaging members interconnected by an interconnecting member. In order to suture together two layers of tissue, the suturing device of the invention is, in one embodiment, placed through holes formed in the two layers of tissue. Each of the two tissue engaging members then engages one of the two layers of tissue. Optionally, a suturing system of the invention includes a cutting member for forming the holes in the layers of tissue.
In one embodiment, the sheath 102 includes a proximal end 116 (i.e., an end that is closest to a physician when the physician is operating the tissue suturing system 100) and an opposite, distal end 118. In one embodiment, the proximal end 116 of the sheath 102 is connected to the interface 110. In another embodiment, the sheath 102 defines a lumen 120 that extends from the proximal end 116 to the distal end 118 of the sheath 102, and an opening 122 located at the distal end 118 of the sheath 102. The opening 122 is in fluid communication with the lumen 120 of the sheath 102. In one embodiment, the sheath 102 is a transseptal sheath, such as, for example, item number RCF-10.0-38-80-J-RB Large Check-Flo® Blue Introducer Set, which is manufactured by Cook Incorporated of Bloomington, Ind.
With continued reference to
The elongate member 104 according to the invention can achieve an extended position and a retracted position. Referring to
In one embodiment, the elongate member 104 is reciprocally moved between the extended and retracted positions by slideable movement of the elongate member 104 within the lumen 120 of the sheath 102 along the longitudinal axis of the sheath 102. Alternatively, the elongate member 104 may be stationary and may be alternated between the extended position and the retracted position by proximally withdrawing the sheath 102 over the elongate member 104 to extend the elongate member 104, and by distally advancing the sheath 102 over the elongate member 104 to retract the elongate member 104.
Referring still to
The delivery member 106 slideably moves within the lumen 130 of the elongate member 104. Accordingly, because the delivery member 106 may be positioned to abut and/or to engageably contact the suturing device 108, slideable movement of the delivery member 106 along a longitudinal axis of the elongate member 104 can result in a corresponding movement of the suturing device 108 along the longitudinal axis of the elongate member 104. In one embodiment, extending the delivery member 106 toward the distal end 126 of the elongate member 104 extends the suturing device 108 toward the distal end 126 of the elongate member 104 and distal to the opening 132 located at the distal end 126 of the elongate member 104.
In one embodiment, the gate member 137 is moveable between an extended position, illustrated in
In one embodiment, the distal end 126 of the elongate member 104 is designed such that the gate member 137 achieves the extended position unless the physician acts to move the gate member 137 from the extended position by, for example, applying a force to or actuating the gate member 137. For example, the distal end 126 of the elongate member 104 may be made of a shape memory material designed to place the gate member 137 in its extended position absent any forces on, or actuation of, the gate member 137. In one such embodiment, one or more actuating strings 127 extend along a length of the elongate member 104 from the proximal end 124 of the elongate member 104 towards the distal end 126 of the elongate member 104. As illustrated in
Alternatively, in another embodiment, the gate member 137 requires actuation to be placed in the extended position. In one such embodiment, the physician places the gate member 137 in the extended position by, for example, rotating the entire, or one or more portions of the, wall 128 at the distal end 126 of the elongate member 104 towards the lumen 130 of the elongate member 104. For example, the physician employs a controller, as described below, to rotate the gate member 137 between the extended position and the retracted position.
In one embodiment, as illustrated in
With reference to
In one embodiment, the elongate member 104 and the delivery member 106 are flexible tubes fabricated from biocompatible materials, such as, for example, polyethylene, polyether-block amide copolymer (e.g., PEBAX®, which is manufactured by Atofina Chemicals of Philadelphia, Pa.), polyurethane, or fluorinated ethylene propylene. In another embodiment, the elongate member 104 and/or the delivery member 106 are made entirely from metal (e.g., stainless steel or Nitinol, which is a nickel-titanium alloy manufactured by Nitinol Devices and Components of Freemont, Calif.). In yet another embodiment, the elongate member 104 and/or the delivery member 106 have a polymer shaft with a metallic tip.
Referring again to
A single controller could, alternatively, control all functions and operations of the tissue suturing system 100 and the instruments disposed therein. Alternatively, a plurality of controllers (e.g., a distal end controller for extending and retracting the distal end of an instrument, a tip bending controller for altering the angular orientation of a portion of an instrument, and an extension controller for extending and retracting a component of an instrument) may be provided, each one controlling different components or functions of the tissue suturing system 100, as is known to one skilled in the art. For example, a separate gate member controller may be provided for extending, retracting, or otherwise manipulating the gate member 137 of the elongate member 104. In yet another embodiment, the physician operates the tissue suturing system 100 by extending, retracting, or otherwise manipulating the elongate member 104, the gate member 137 of the elongate member 104, and the delivery device 106 manually, without the use of any controllers.
With reference to
Referring again to
In one embodiment, the first interconnecting member 144 is connected at its first fixed end 154 to the first tissue engaging member 140 and at its second fixed end 156 to the second tissue engaging member 142 by, for example, an adhesive, such as a glue. Alternatively, the first interconnecting member 144 includes a first hinge 158 at its first fixed end 154 and a second hinge 160 at its second fixed end 156. In one such embodiment, the first hinge 158 connects the first interconnecting member 144 to the first tissue engaging member 140 and the second hinge 160 connects the first interconnecting member 144 to the second tissue engaging member 142. In one embodiment, the first hinge 158 and the second hinge 160 allow for rotational movement of the first tissue engaging member 140 and the second tissue engaging member 142, respectively, relative to each other and relative to the first interconnecting member 144.
In one embodiment, the suturing device 108 is pre-assembled (e.g., manufactured) so that the first interconnecting member 144 continuously connects the first tissue engaging member 140 to the second tissue engaging member 142. In other words, the physician need not, at any point during his or her use of the suturing system 100, connect one portion of the first interconnecting member 144 to another portion of the first interconnecting member 144, or connect either one of the two tissue engaging members 140, 142 to the first interconnecting member 144. Rather, the suturing device 108 is insertable into a patient in its connected configuration, illustrated in, and described with respect to, for example,
In one embodiment, the first interconnecting member 144 is made from a flexible yet resilient material, allowing the first interconnecting member 144 to alternate between a deformed position (e.g., a bent position), as illustrated in
Referring to
Exemplary resilient materials from which the first interconnecting member 144 can be manufactured include bioabsorbable materials such as, but not exclusively, polylactic acid (PLA), polyethylene glycol (PEG), polycaprolactone (PCL), polyglycolic acid (PGA), or magnesium, non-resorbable materials such as, but not exclusively, a metal (e.g., nitinol) or a polymer (e.g., urethane), and/or rubber.
In some embodiments of the invention, the first interconnecting member 144 of the suturing device 108 possesses elastic properties. For example, in one embodiment, the first interconnecting member 144 can be stretched, and thereafter returned to its original state when the stretching force is removed. More particularly, in one embodiment, as the first interconnecting member 144 is stretched, moving the first tissue engaging member 140 away from the second tissue engaging member 142, a restoring force is generated in the first interconnecting member 144. The restoring force acts to pull the first tissue engaging member 140 back towards the second tissue engaging member 142 when the stretching force is removed. Exemplary elastic materials from which the first interconnecting member 144 can be manufactured include bioabsorbable materials such as, but not exclusively, polylactic acid (PLA), polyethylene glycol (PEG), polycaprolactone (PCL), or polyglycolic acid (PGA), non-resorbable materials such as, but not exclusively, a polymer or a polymer blend (e.g., urethane), and/or rubber.
Referring now to
In one embodiment, the first interconnecting member 144 has a length of between about 1.0 mm and about 20.0 mm and a cross-sectional diameter between about 0.01 mm and about 2.0 mm. In another embodiment, a tissue engaging member, for example the first tissue engaging member 140, has a length 162 from about 1.0 mm to about 20.0 mm and a cross-sectional diameter 164 from about 0.05 mm to about 5.0 mm.
In one embodiment, referring still to
Some or all of the tissue engaging members 140, 140′, 142, 142′, 168, the interconnecting members 144, 144′, 178, and the tightening mechanism 180 may be manufactured from a bioabsorbable material that, following placement in the patient's body, biodegrades over time and is absorbed into the patient's body, such as, for example, polylactic acid (PLA), polyethylene glycol (PEG), polycaprolactone (PCL), polyglycolic acid (PGA), or magnesium. In other embodiments, some or all of the tissue engaging members 140, 140′, 142, 142′, 168, the interconnecting members 144, 144′, 178, and the tightening mechanism 180 may be manufactured from a biological material (e.g., an extracellular matrix material) that allows for tissue ingrowth when the suturing device 108, 108′ is implanted within a patient's tissues. In yet other embodiments, some or all of the tissue engaging members 140, 140′, 142, 142′, 168, the interconnecting members 144, 144′, 178, and the tightening mechanism 180 are coated and/or impregnated with a material (e.g., a reactive material) for stimulating tissue growth. In one embodiment, the growth stimulating material is collagen. In another embodiment, the growth stimulating material is a growth factor, such as a vascular endothelial growth factor, a basic fibro growth factor, or an angiogenic growth factor. In yet another embodiment, the growth stimulating material is a pharmacological agent for stimulating tissue growth, such as, for example, cells or genes. Alternatively, in still another embodiment, the growth stimulating material is an irritant for encouraging an inflammatory response, such as, for example, cotton seed oil or alcohol.
Materials that are not bio-absorbable could, alternatively, be used to manufacture different parts of the suturing device 108, 108′. The tissue engaging members 140, 140′, 142, 142′, 168 and/or the tightening mechanism 180 could, for example, be manufactured using a polymer material, (e.g., polyethylene, nylon, polypropylene, polyester, or polyurethane), a shape memory material, or a metal. For their part, the interconnecting members 144, 144′, 178 could, for example, be manufactured using a polymer material, (e.g., polyethylene or polyurethane), a shape memory material, a metal, a thread, a spring, or an elastomer. For example, the tissue engaging members 140, 140′, 142, 142′, 168, and the interconnecting members 144, 144′, 178 could be manufactured using a nickel-titanium alloy, such as Nitinol. As another example, the tissue engaging members 140, 140′, 142, 142′, 168, and the interconnecting members 144, 144′, 178 can be manufactured as an integral unit by, for example, molding or stamping them from a single piece of material, such as a polymer.
In yet another embodiment, some or all of the tissue engaging members 140, 140′, 142, 142′, 168, the interconnecting members 144, 144′, 178, and the tightening mechanism 180 are coated with a material that reduces thrombosis, such as, for example, heparin. In still another embodiment, some or all of the tissue engaging members 140, 140′, 142, 142′, 168, the interconnecting members 144, 144′, 178, and the tightening mechanism 180 include a radiopaque material.
In another aspect, the invention provides a method for suturing tissue.
Optionally, as illustrated in
In one embodiment, the physician positions the tissue stabilization device 184 within and through the patent foramen ovale 52 between the septum secundum 62 and the septum primum 60 of the patient's heart. The tissue stabilization device 184 is used by the physician to, for example, limit movement of the septum secundum 62 and the septum primum 60 prior to forming, as explained below, holes through the septum secundum 62 and the septum primum 60 with the cutting member 134 of the elongate member 104. The tissue stabilization device 184 also serves to position the distal end 187 of the catheter 185 in the area where the septum secundum 62 and the septum primum 60 overlap. Accordingly, when the elongate member 104 is extended to exit through the opening 191 at the distal end 187 of the catheter 185, the cutting member 134 of the elongate member 104 pierces holes through the septum secundum 62 and the septum primum 60 in the area where they overlap. In accordance with the method further described below, the suturing device 108 is thereby placed through the septa 60, 62 in the area where they overlap.
Exemplary tissue stabilization devices and flexible members suitable for stabilizing cardiac tissues in a patient and for placing the elements described above in the area where the septum secundum 62 and the septum primum 60 overlap include those described in U.S. patent application Ser. No. 10/660,444, the disclosure of which is hereby incorporated herein by reference in its entirety. For example, the tissue stabilization device 184 may: i) be a flexible coil having a spiral shape, illustrated in
Alternatively, in another embodiment, the physician does not employ the tissue stabilization device 184 in suturing the patent foramen ovale 52. Accordingly, while
Referring now to
Referring now to
Referring now to
In other embodiments, to deliver a suturing device 108, 108′ that includes a series of alternating tissue engaging members and interconnecting members, as illustrated in
It should be understood that the order of the steps in the above described methods and/or the order for performing certain actions is immaterial so long as the invention remains operable. Moreover, two or more steps or actions may be conducted simultaneously.
Certain embodiments of the present invention were described above. It is, however, expressly noted that the present invention is not limited to those embodiments, but rather the intention is that additions and modifications to what was expressly described herein are also included within the scope of the invention. Moreover, it is to be understood that the features of the various embodiments described herein were not mutually exclusive and can exist in various combinations and permutations, even if such combinations or permutations were not made express herein, without departing from the spirit and scope of the invention. In fact, variations, modifications, and other implementations of what was described herein will occur to those of ordinary skill in the art without departing from the spirit and the scope of the invention. As such, the invention is not to be defined only by the preceding illustrative description.
This application incorporates by reference, and claims priority to and the benefit of, U.S. provisional application Ser. No. 60/501,948, which was filed on Sep. 11, 2003.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3077733 | Axe et al. | Feb 1963 | A |
| 3103666 | Bone | Sep 1963 | A |
| 3470834 | Bone | Oct 1969 | A |
| 3716058 | Tanner, Jr. | Feb 1973 | A |
| 3874388 | King et al. | Apr 1975 | A |
| 3875648 | Bone | Apr 1975 | A |
| 3990619 | Russell | Nov 1976 | A |
| 4006747 | Kronenthal et al. | Feb 1977 | A |
| 4007743 | Blake | Feb 1977 | A |
| 4039078 | Bone | Aug 1977 | A |
| 4235238 | Ogiu et al. | Nov 1980 | A |
| 4394864 | Sandhaus | Jul 1983 | A |
| 4425908 | Simon | Jan 1984 | A |
| 4485816 | Krumme | Dec 1984 | A |
| 4515583 | Sorich | May 1985 | A |
| 4556050 | Hodgson | Dec 1985 | A |
| 4586502 | Bedi et al. | May 1986 | A |
| 4669473 | Richards et al. | Jun 1987 | A |
| 4696300 | Anderson | Sep 1987 | A |
| 4705040 | Mueller et al. | Nov 1987 | A |
| 4799483 | Kraff | Jan 1989 | A |
| 4800890 | Cramer | Jan 1989 | A |
| 4834096 | Oh et al. | May 1989 | A |
| 4836204 | Landymore et al. | Jun 1989 | A |
| 4844066 | Stein | Jul 1989 | A |
| 4915107 | Rebuffat et al. | Apr 1990 | A |
| 4985014 | Orejola | Jan 1991 | A |
| 5021059 | Kensey et al. | Jun 1991 | A |
| 5030199 | Barwick et al. | Jul 1991 | A |
| 5037433 | Wilk et al. | Aug 1991 | A |
| 5041129 | Hayhurst et al. | Aug 1991 | A |
| 5042976 | Ishitsu et al. | Aug 1991 | A |
| 5049153 | Nakao et al. | Sep 1991 | A |
| 5057114 | Wittich et al. | Oct 1991 | A |
| 5073166 | Parks et al. | Dec 1991 | A |
| 5108420 | Marks | Apr 1992 | A |
| 5112310 | Grobe | May 1992 | A |
| 5171259 | Inoue | Dec 1992 | A |
| 5190528 | Fonger et al. | Mar 1993 | A |
| 5192301 | Kamiya et al. | Mar 1993 | A |
| 5222974 | Kensey et al. | Jun 1993 | A |
| 5236440 | Hlavacek | Aug 1993 | A |
| 5257637 | Gazayerli | Nov 1993 | A |
| 5282827 | Kensey et al. | Feb 1994 | A |
| 5284488 | Sideris | Feb 1994 | A |
| 5304184 | Hathaway et al. | Apr 1994 | A |
| 5304185 | Taylor | Apr 1994 | A |
| 5312341 | Turi | May 1994 | A |
| 5312435 | Nash et al. | May 1994 | A |
| 5320633 | Allen et al. | Jun 1994 | A |
| 5334217 | Das | Aug 1994 | A |
| 5336252 | Cohen | Aug 1994 | A |
| 5354308 | Simon et al. | Oct 1994 | A |
| 5357979 | Imran | Oct 1994 | A |
| 5370661 | Branch | Dec 1994 | A |
| 5403338 | Milo | Apr 1995 | A |
| 5411481 | Allen et al. | May 1995 | A |
| 5413584 | Schulze | May 1995 | A |
| 5417699 | Klein et al. | May 1995 | A |
| 5417700 | Egan | May 1995 | A |
| 5425744 | Fagan et al. | Jun 1995 | A |
| 5433727 | Sideris | Jul 1995 | A |
| 5451235 | Lock et al. | Sep 1995 | A |
| 5470337 | Moss | Nov 1995 | A |
| 5478353 | Yoon | Dec 1995 | A |
| 5486185 | Freitas et al. | Jan 1996 | A |
| 5486193 | Bourne et al. | Jan 1996 | A |
| 5507811 | Koike et al. | Apr 1996 | A |
| 5540712 | Kleshinski et al. | Jul 1996 | A |
| 5545138 | Fugoso et al. | Aug 1996 | A |
| 5573542 | Stevens | Nov 1996 | A |
| 5577299 | Thompson et al. | Nov 1996 | A |
| 5578045 | Das | Nov 1996 | A |
| 5597378 | Jervis | Jan 1997 | A |
| 5601571 | Moss | Feb 1997 | A |
| 5601575 | Measamer et al. | Feb 1997 | A |
| 5618311 | Gryskiewicz | Apr 1997 | A |
| 5620461 | Muijs Van De Moer et al. | Apr 1997 | A |
| 5634936 | Linden et al. | Jun 1997 | A |
| 5649959 | Hannam et al. | Jul 1997 | A |
| 5683411 | Kavteladze et al. | Nov 1997 | A |
| 5702421 | Schneidt | Dec 1997 | A |
| 5709707 | Lock et al. | Jan 1998 | A |
| 5713908 | Jameel et al. | Feb 1998 | A |
| 5720754 | Middleman et al. | Feb 1998 | A |
| 5725552 | Kotula et al. | Mar 1998 | A |
| 5733294 | Forber et al. | Mar 1998 | A |
| 5733337 | Carr, Jr. et al. | Mar 1998 | A |
| 5741297 | Simon | Apr 1998 | A |
| 5746765 | Kleshinski et al. | May 1998 | A |
| 5749895 | Sawyer et al. | May 1998 | A |
| 5776162 | Kleshinski et al. | Jul 1998 | A |
| 5797960 | Stevens et al. | Aug 1998 | A |
| 5800516 | Fine et al. | Sep 1998 | A |
| 5810848 | Hayhurst | Sep 1998 | A |
| 5810884 | Kim | Sep 1998 | A |
| 5823956 | Roth et al. | Oct 1998 | A |
| 5827216 | Igo et al. | Oct 1998 | A |
| 5829447 | Stevens et al. | Nov 1998 | A |
| 5836311 | Borst et al. | Nov 1998 | A |
| 5853422 | Huebsch et al. | Dec 1998 | A |
| 5855614 | Stevens et al. | Jan 1999 | A |
| 5861003 | Latson et al. | Jan 1999 | A |
| 5868753 | Schatz | Feb 1999 | A |
| 5879366 | Shaw et al. | Mar 1999 | A |
| 5885238 | Stevens et al. | Mar 1999 | A |
| 5893856 | Jacob et al. | Apr 1999 | A |
| 5895404 | Ruiz | Apr 1999 | A |
| 5902317 | Kleshinski et al. | May 1999 | A |
| 5902319 | Daley | May 1999 | A |
| 5904703 | Gilson | May 1999 | A |
| 5919200 | Stambaugh et al. | Jul 1999 | A |
| 5924424 | Stevens et al. | Jul 1999 | A |
| 5927284 | Borst et al. | Jul 1999 | A |
| 5928250 | Koike et al. | Jul 1999 | A |
| 5944738 | Amplatz et al. | Aug 1999 | A |
| 5964782 | Lafontaine et al. | Oct 1999 | A |
| 5976174 | Ruiz | Nov 1999 | A |
| 5989268 | Pugsley, Jr. et al. | Nov 1999 | A |
| 5993475 | Lin et al. | Nov 1999 | A |
| 5997556 | Tanner | Dec 1999 | A |
| 5997562 | Zadno-Azizi et al. | Dec 1999 | A |
| 6001085 | Lurie et al. | Dec 1999 | A |
| 6007558 | Ravenscroft et al. | Dec 1999 | A |
| 6010517 | Baccaro | Jan 2000 | A |
| 6015378 | Borst et al. | Jan 2000 | A |
| 6024756 | Huebsch et al. | Feb 2000 | A |
| 6030007 | Bassily et al. | Feb 2000 | A |
| 6030405 | Zarbatany et al. | Feb 2000 | A |
| 6056760 | Koike et al. | May 2000 | A |
| 6077291 | Das | Jun 2000 | A |
| 6079414 | Roth | Jun 2000 | A |
| 6080182 | Shaw et al. | Jun 2000 | A |
| 6086610 | Duerig et al. | Jul 2000 | A |
| 6113609 | Adams | Sep 2000 | A |
| 6117159 | Huebsch et al. | Sep 2000 | A |
| 6129755 | Mathis et al. | Oct 2000 | A |
| 6132438 | Fleischman et al. | Oct 2000 | A |
| 6142975 | Jalisi et al. | Nov 2000 | A |
| 6149664 | Kurz | Nov 2000 | A |
| 6152918 | Padilla et al. | Nov 2000 | A |
| 6162202 | Sicurelli et al. | Dec 2000 | A |
| 6165183 | Kuehn et al. | Dec 2000 | A |
| 6165204 | Levinson et al. | Dec 2000 | A |
| 6171329 | Shaw et al. | Jan 2001 | B1 |
| 6174322 | Schneidt | Jan 2001 | B1 |
| 6200313 | Abe et al. | Mar 2001 | B1 |
| 6206895 | Levinson | Mar 2001 | B1 |
| 6206907 | Marino et al. | Mar 2001 | B1 |
| 6206921 | Guagliano et al. | Mar 2001 | B1 |
| 6214029 | Thill et al. | Apr 2001 | B1 |
| 6217590 | Levinson | Apr 2001 | B1 |
| 6221092 | Koike et al. | Apr 2001 | B1 |
| 6228097 | Levinson et al. | May 2001 | B1 |
| 6231561 | Frazier et al. | May 2001 | B1 |
| 6245080 | Levinson | Jun 2001 | B1 |
| 6254550 | McNamara et al. | Jul 2001 | B1 |
| 6258026 | Ravenscroft et al. | Jul 2001 | B1 |
| 6270515 | Linden et al. | Aug 2001 | B1 |
| 6277138 | Levinson et al. | Aug 2001 | B1 |
| 6277139 | Levinson et al. | Aug 2001 | B1 |
| 6278371 | Hopkins | Aug 2001 | B1 |
| 6290674 | Roue et al. | Sep 2001 | B1 |
| 6302903 | Mulier et al. | Oct 2001 | B1 |
| 6306150 | Levinson | Oct 2001 | B1 |
| 6312446 | Huebsch et al. | Nov 2001 | B1 |
| 6319263 | Levinson | Nov 2001 | B1 |
| 6322548 | Payne et al. | Nov 2001 | B1 |
| 6325807 | Que | Dec 2001 | B1 |
| 6328688 | Borst et al. | Dec 2001 | B1 |
| 6332877 | Michels | Dec 2001 | B1 |
| 6334843 | Borst et al. | Jan 2002 | B1 |
| 6336898 | Borst et al. | Jan 2002 | B1 |
| 6342064 | Koike et al. | Jan 2002 | B1 |
| 6344049 | Levinson et al. | Feb 2002 | B1 |
| 6346074 | Roth | Feb 2002 | B1 |
| 6348041 | Klint | Feb 2002 | B1 |
| 6348059 | Hathaway et al. | Feb 2002 | B1 |
| 6350229 | Borst et al. | Feb 2002 | B1 |
| 6352531 | O'Connor et al. | Mar 2002 | B1 |
| 6352552 | Levinson et al. | Mar 2002 | B1 |
| 6355052 | Neuss et al. | Mar 2002 | B1 |
| 6364826 | Borst et al. | Apr 2002 | B1 |
| 6364846 | Nakamura | Apr 2002 | B1 |
| 6364853 | French et al. | Apr 2002 | B1 |
| 6364876 | Erb et al. | Apr 2002 | B1 |
| 6371906 | Borst et al. | Apr 2002 | B1 |
| 6371971 | Tsugita et al. | Apr 2002 | B1 |
| 6375625 | French et al. | Apr 2002 | B1 |
| 6375635 | Moutafis et al. | Apr 2002 | B1 |
| 6375671 | Kobayashi et al. | Apr 2002 | B1 |
| 6379342 | Levinson | Apr 2002 | B1 |
| 6379368 | Corcoran et al. | Apr 2002 | B1 |
| 6387104 | Pugsley, Jr. et al. | May 2002 | B1 |
| 6394948 | Borst et al. | May 2002 | B1 |
| 6398796 | Levinson | Jun 2002 | B2 |
| 6402772 | Amplatz et al. | Jun 2002 | B1 |
| 6440152 | Gainor et al. | Aug 2002 | B1 |
| 6458100 | Roue et al. | Oct 2002 | B2 |
| 6460749 | Levinson et al. | Oct 2002 | B1 |
| 6464629 | Boone et al. | Oct 2002 | B1 |
| 6464630 | Borst et al. | Oct 2002 | B1 |
| 6482210 | Skiba et al. | Nov 2002 | B1 |
| 6482224 | Michler et al. | Nov 2002 | B1 |
| 6488706 | Solymar | Dec 2002 | B1 |
| 6494888 | Laufer et al. | Dec 2002 | B1 |
| 6527786 | Davis et al. | Mar 2003 | B1 |
| 6537198 | Vidlund et al. | Mar 2003 | B1 |
| 6544274 | Danitz et al. | Apr 2003 | B2 |
| 6551344 | Thill | Apr 2003 | B2 |
| 6572593 | Daum | Jun 2003 | B1 |
| 6596013 | Yang et al. | Jul 2003 | B2 |
| 6606513 | Lardo et al. | Aug 2003 | B2 |
| 6623508 | Shaw et al. | Sep 2003 | B2 |
| 6623518 | Thompson et al. | Sep 2003 | B2 |
| RE38335 | Aust et al. | Nov 2003 | E |
| 6650923 | Lesh et al. | Nov 2003 | B1 |
| 6652486 | Bialecki et al. | Nov 2003 | B2 |
| 6663592 | Rhad et al. | Dec 2003 | B2 |
| 6685724 | Haluck | Feb 2004 | B1 |
| 6692471 | Boudreaux | Feb 2004 | B2 |
| 6702835 | Ginn | Mar 2004 | B2 |
| 6712804 | Roue et al. | Mar 2004 | B2 |
| 6712836 | Berg et al. | Mar 2004 | B1 |
| 6730062 | Hoffman et al. | May 2004 | B2 |
| 6730081 | Desai | May 2004 | B1 |
| 6855124 | Gonzalez et al. | Feb 2005 | B1 |
| 6939348 | Malecki et al. | Sep 2005 | B2 |
| 7220265 | Chanduszko et al. | May 2007 | B2 |
| 20010014800 | Frazier et al. | Aug 2001 | A1 |
| 20010034537 | Shaw et al. | Oct 2001 | A1 |
| 20010037129 | Thill | Nov 2001 | A1 |
| 20010039435 | Roue et al. | Nov 2001 | A1 |
| 20010044639 | Levinson | Nov 2001 | A1 |
| 20010049492 | Frazier et al. | Dec 2001 | A1 |
| 20020002373 | Boehlke et al. | Jan 2002 | A1 |
| 20020010481 | Jayaraman | Jan 2002 | A1 |
| 20020019648 | Akerfeldt et al. | Feb 2002 | A1 |
| 20020026094 | Roth | Feb 2002 | A1 |
| 20020026208 | Roe et al. | Feb 2002 | A1 |
| 20020029048 | Miller | Mar 2002 | A1 |
| 20020032462 | Houser et al. | Mar 2002 | A1 |
| 20020043307 | Ishida et al. | Apr 2002 | A1 |
| 20020045908 | Nobles et al. | Apr 2002 | A1 |
| 20020052572 | Franco et al. | May 2002 | A1 |
| 20020077555 | Schwartz | Jun 2002 | A1 |
| 20020096183 | Stevens et al. | Jul 2002 | A1 |
| 20020099389 | Michler et al. | Jul 2002 | A1 |
| 20020107531 | Schreck et al. | Aug 2002 | A1 |
| 20020120323 | Thompson et al. | Aug 2002 | A1 |
| 20020128680 | Pavlovic | Sep 2002 | A1 |
| 20020129819 | Feldman et al. | Sep 2002 | A1 |
| 20020169377 | Khairkhahan et al. | Nov 2002 | A1 |
| 20020183786 | Girton | Dec 2002 | A1 |
| 20020183787 | Wahr et al. | Dec 2002 | A1 |
| 20030028213 | Thill et al. | Feb 2003 | A1 |
| 20030045893 | Ginn | Mar 2003 | A1 |
| 20030050665 | Ginn | Mar 2003 | A1 |
| 20030059640 | Marton et al. | Mar 2003 | A1 |
| 20030100920 | Akin et al. | May 2003 | A1 |
| 20030139819 | Beer et al. | Jul 2003 | A1 |
| 20030144694 | Chanduszko et al. | Jul 2003 | A1 |
| 20030167055 | Kolata et al. | Sep 2003 | A1 |
| 20030181937 | Osterlind | Sep 2003 | A1 |
| 20030191494 | Gray et al. | Oct 2003 | A1 |
| 20030195530 | Thill | Oct 2003 | A1 |
| 20030195531 | Gardiner et al. | Oct 2003 | A1 |
| 20030208232 | Blaeser et al. | Nov 2003 | A1 |
| 20030212435 | Gold et al. | Nov 2003 | A1 |
| 20040138701 | Haluck | Jul 2004 | A1 |
| 20040193147 | Malecki et al. | Sep 2004 | A1 |
| 20040230185 | Malecki et al. | Nov 2004 | A1 |
| 20040243122 | Auth et al. | Dec 2004 | A1 |
| 20040267191 | Gifford, III et al. | Dec 2004 | A1 |
| 20050021016 | Malecki et al. | Jan 2005 | A1 |
| 20050034735 | Deem et al. | Feb 2005 | A1 |
| 20050080406 | Malecki et al. | Apr 2005 | A1 |
| 20050101984 | Chanduszko et al. | May 2005 | A1 |
| 20050131401 | Malecki et al. | Jun 2005 | A1 |
| 20050131460 | Gifford, III et al. | Jun 2005 | A1 |
| 20060027241 | Malecki et al. | Feb 2006 | A1 |
| 20060074410 | Malecki et al. | Apr 2006 | A1 |
| Number | Date | Country |
|---|---|---|
| 553259 | Mar 1995 | EP |
| 1 013 227 | Jun 2000 | EP |
| 1 046 375 | Oct 2000 | EP |
| 724406 | Dec 2001 | EP |
| 1222897 | Jul 2002 | EP |
| WO 9206733 | Apr 1992 | WO |
| WO 9510983 | Apr 1995 | WO |
| WO 9513111 | May 1995 | WO |
| WO 9807375 | Feb 1998 | WO |
| WO 9918862 | Apr 1999 | WO |
| WO 9918864 | Apr 1999 | WO |
| WO 9918870 | Apr 1999 | WO |
| WO 9918871 | Apr 1999 | WO |
| WO 9925254 | May 1999 | WO |
| WO 0027292 | May 2000 | WO |
| WO 0149185 | Jul 2001 | WO |
| WO 0178596 | Oct 2001 | WO |
| WO 0241790 | May 2002 | WO |
| WO 03022159 | Mar 2003 | WO |
| WO 03059152 | Jul 2003 | WO |
| WO 03077733 | Sep 2003 | WO |
| WO 03088818 | Dec 2003 | WO |
| WO 2004028348 | Apr 2004 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20050059984 A1 | Mar 2005 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60501948 | Sep 2003 | US |